TheraRadar
← Back
Data updated: Jul 17, 2026

LOCH

Generics

LOCH is a generic drug manufacturer focused on Dermatology.

1988
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

LOCH's Key Drugs

LOCH's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LOCH's Recent FDA Approvals

New NDA/BLA approvals for LOCH over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LOCH's Therapeutic Areas

LOCH's approved drugs and pipeline span 1 therapeutic area, led by Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
1 drugs

LOCH's Top Competitors

LOCH's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LOCH Pipeline Snapshot

Active clinical trials for LOCH across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling